Genetic Study Finds Potential Link Between GLP-1 Drugs and Brain Health

A class of drugs widely used to manage type 2 diabetes and obesity may offer new clues about brain health. Researchers studying GLP-1 receptor agonists, the group of medicines that includes Ozempic, have identified genetic evidence linking their activity to lower odds of stroke and Alzheimer’s disease.

The findings, published on September 25, 2026, in Neurology: Genetics, suggest that the biological pathways targeted by these medicines may be associated with neurological health. However, the study does not prove that taking Ozempic prevents stroke or Alzheimer’s disease.

The distinction matters. Genetic associations can help scientists identify promising research directions, but they do not automatically establish the benefits of a prescription drug in everyday clinical use.

What Did the Researchers Discover?

The researchers used a method called Mendelian randomisation to investigate possible relationships between GLP-1 receptor activity and neurological conditions. The technique examines genetic variations linked to specific biological pathways to assess whether those variations may be associated with particular health outcomes.

Using large genetic datasets representing people of European, East Asian and African ancestry, the researchers identified several associations.

The analysis linked genetically predicted effects associated with GLP-1 receptor agonism to 25% lower odds of stroke and 49% lower odds of Alzheimer’s disease.

The researchers also found associations with 28% lower odds of ischaemic stroke, which occurs when a blockage restricts blood flow to the brain, and 45% lower odds of cardioembolic stroke, which happens when a blood clot originating in the heart travels to the brain.

Other findings pointed to potential associations involving heart failure and indicators related to small-vessel disease in the brain.

These results raise questions about how metabolic health and neurological conditions may interact. Stroke and Alzheimer’s disease develop through different processes, although cardiovascular and metabolic factors can influence overall brain health.

The percentages, however, describe associations identified through genetic analysis. They are not estimates of the benefits that patients would necessarily receive from taking Ozempic.

How Could Diabetes Medicines Affect the Brain?

GLP-1 receptor agonists mimic a naturally occurring hormone involved in blood glucose regulation, appetite and digestion. Semaglutide, the active ingredient in Ozempic and Wegovy, belongs to this drug class.

Doctors prescribe these medicines for conditions including type 2 diabetes and obesity, depending on the specific drug and its approved uses.

Scientists are now examining whether their effects extend beyond blood sugar control and weight management. Changes in cardiovascular health, metabolic function and inflammation could potentially influence biological processes associated with neurological disease.

Better management of certain cardiovascular and metabolic risk factors may support brain health. Yet researchers have not established which mechanisms explain the associations reported in this study.

The genetic approach also has limits. It investigates the effects associated with inherited genetic variations, rather than directly measuring the long-term effects of taking a particular medicine.

Consequently, the findings cannot establish whether semaglutide itself would produce the same outcomes, at what dose any benefit might occur, or which patients could benefit.

Does Ozempic Prevent Alzheimer’s Disease?

No. Current evidence does not establish Ozempic as a preventive treatment for Alzheimer’s disease or stroke.

The reported 49% lower odds of Alzheimer’s disease refer to the genetic associations identified in the analysis. They do not mean that people taking Ozempic experience a 49% reduction in their personal risk of developing the condition.

Clinical trials are needed to determine whether the drug can reduce disease incidence in people who are otherwise at risk.

Evidence from separate phase 3 trials, EVOKE and EVOKE+, adds another layer to the discussion. These trials found that oral semaglutide did not significantly slow clinical progression in people who already had early Alzheimer’s disease.

Those results do not necessarily answer whether GLP-1 medicines could affect disease development before symptoms appear. Preventing a condition and slowing its progression after diagnosis are different research questions.

Still, the trial findings reinforce the need to distinguish promising biological evidence from a treatment benefit demonstrated in patients.

What Happens Next?

Further research will need to test whether the genetic associations translate into measurable clinical benefits. Scientists must also establish which groups, if any, might benefit and identify the biological processes behind the observed relationships.

For now, Ozempic remains a medicine used for its approved indications, not a proven way to prevent stroke or Alzheimer’s disease.

People prescribed GLP-1 receptor agonists should continue following their doctors’ advice and should not start, stop or change medication solely because of these findings.

The study provides a new direction for research into metabolic medicines and brain health. Whether those findings eventually lead to effective strategies for protecting the ageing brain remains an open question.